The Liira (Lipids, Inflammation and Cardiovascular Risk in RA) study conducted from 2016 to 2021 included 66 RA patients over 35 years of age (who had no coronary artery disease or hyperlipidemia and with a mean duration of RA of 7.4 years) with active disease about to initiate anti-TNF-α therapy. The gene discussed is TNF; the disease is rheumatoid arthritis.